Halozyme Therapeutics Inc. (Nasdaq: HALO) widened first quarter losses to 22 cents per share from 17 cents per share a year earlier but the company announced that the Data Monitoring Committee now supported continued enrollment of patients in clinical trials for PEGPH20. The stock price climbed 96 cents to $8.48.
DMC Suppports Halozyme Trial
May 13, 2014 at 13:27 PM EDT
